Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Varrone

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Molecular Imaging and Biology|March 17, 2026
The Binding of the High Affinity Radioligand Fallypride to the D2-dopamine Receptor is Sensitive to Injected Mass - a PET Study in RodentsMiklós Tóth, Lenke Tari, Sangram Nag, et al.
Journal of Neuroinflammation|November 14, 2025
A [<sup>11</sup>C]PBR28 PET study on the associations between sleep health and microglial densityLeonie Jt Balter, Jonatan Malmros, Per Stenkrona, et al.
Neurobiology of Aging|March 21, 2017
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development frameworkKonstantinos Chiotis, Laure Saint-Aubert, Marina Boccardi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 21, 2015
Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson DiseasePatrik Fazio, Per Svenningsson, Anton Forsberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 13, 2016
Guidelines to PET measurements of the target occupancy in the brain for drug developmentAkihiro Takano, Andrea Varrone, Balázs Gulyás, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 2008
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2Marianna Amboni, Maria Teresa Pellecchia, Autilia Cozzolino, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 20, 2008
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CITAndrea Varrone, Valeria Sansone, Maria Teresa Pellecchia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2007
Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET studyAkihiro Takano, Christer Halldin, Andrea Varrone, et al.
EJNMMI Research|June 14, 2025
Test-retest properties of [<sup>11</sup>C]PXT012253 as a positron emission tomography (PET) radiotracer in healthy human brain: PET imaging of mGlu4Per Stenkrona, Ryosuke Arakawa, Jiamei Guo, et al.
Nuclear Medicine Communications|December 15, 2021
VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECTSusanna Jakobson Mo, Jan Axelsson, Lars J Stiernman, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Molecular Imaging and Biology|March 17, 2026
The Binding of the High Affinity Radioligand Fallypride to the D2-dopamine Receptor is Sensitive to Injected Mass - a PET Study in RodentsMiklós Tóth, Lenke Tari, Sangram Nag, et al.
Journal of Neuroinflammation|November 14, 2025
A [<sup>11</sup>C]PBR28 PET study on the associations between sleep health and microglial densityLeonie Jt Balter, Jonatan Malmros, Per Stenkrona, et al.
Neurobiology of Aging|March 21, 2017
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development frameworkKonstantinos Chiotis, Laure Saint-Aubert, Marina Boccardi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 21, 2015
Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson DiseasePatrik Fazio, Per Svenningsson, Anton Forsberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 13, 2016
Guidelines to PET measurements of the target occupancy in the brain for drug developmentAkihiro Takano, Andrea Varrone, Balázs Gulyás, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 2008
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2Marianna Amboni, Maria Teresa Pellecchia, Autilia Cozzolino, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 20, 2008
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CITAndrea Varrone, Valeria Sansone, Maria Teresa Pellecchia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2007
Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET studyAkihiro Takano, Christer Halldin, Andrea Varrone, et al.
EJNMMI Research|June 14, 2025
Test-retest properties of [<sup>11</sup>C]PXT012253 as a positron emission tomography (PET) radiotracer in healthy human brain: PET imaging of mGlu4Per Stenkrona, Ryosuke Arakawa, Jiamei Guo, et al.
Nuclear Medicine Communications|December 15, 2021
VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECTSusanna Jakobson Mo, Jan Axelsson, Lars J Stiernman, et al.
Pageof 17